Following this cycle, the patient demonstrated significant improvement in cell counts; however, minimal residual tumor cells remained, evidenced by the presence of rare scattered CD56, chromogranin, and synaptophysin-positive cells. This evidence concerns the gene NCAM1 and neoplasm.